Leadership Overview
Roche has 10 executives leading key functions including operational scaling, technological innovation, regional market management, and strategic governance.
Driven by a commitment to personalized healthcare, Roche advances science to improve patient outcomes through integrated pharmaceutical and diagnostic solutions across global markets.
Driven by a commitment to personalized healthcare, Roche advances science to improve patient outcomes through integrated pharmaceutical and diagnostic solutions across global markets.
Leadership Roles at Roche
Avi Danziger - Chief Executive Officer, Roche (Israel)
Avi Danziger, the Chief Executive Officer, Roche (Israel) at Roche, directs the overall strategic vision and business operations within the Israeli market. Overseeing the integration of pharmaceutical and diagnostic divisions, the Chief Executive Officer, Roche (Israel) ensures that the company delivers high-value healthcare solutions to local patients. This leadership role involves engaging with government health authorities and academic partners to foster innovation in personalized medicine. By driving local growth and maintaining operational excellence, Avi Danziger secures the company's competitive position in the region. Ultimately, Danziger leads the local team in executing the global mission, ensuring that the company's commitment to advancing science translates into meaningful improvements for the health and well-being of the population.
Peter Refler - Chief Financial Officer, Finance & Director, Roche Pharma (Vietnam)
Peter Refler, the Chief Financial Officer, Finance & Director, Roche Pharma (Vietnam) at Roche, manages the financial health and strategic direction of the pharmaceutical operations in Vietnam. Overseeing budget allocation and financial reporting, the Chief Financial Officer, Finance & Director, Roche Pharma (Vietnam) ensures that resources support the development and distribution of essential medicines. This role involves navigating the local economic landscape to drive sustainable revenue growth. By providing financial oversight and strategic guidance, Peter Refler enables the local team to expand access to innovative treatments. Ultimately, Refler secures the financial stability of the regional operations, ensuring that the company continues to invest in research and development while meeting the healthcare needs of the Vietnamese market.
Diego Radiati - Chief Financial Officer, Country
Diego Radiati, the Chief Financial Officer, Country at Roche, manages the financial operations and fiscal strategy for the national business unit. Overseeing capital expenditure and financial risk management, the Chief Financial Officer, Country ensures that the company maintains the resources necessary to support its diagnostic and pharmaceutical activities. This role involves collaborating with other regional leaders to optimize cost structures and improve operational efficiency. By providing accurate financial insights, Diego Radiati enables the leadership team to make informed decisions regarding market expansion and product investment. Ultimately, Radiati secures the financial foundation of the country-level operations, ensuring that the company remains well-positioned to deliver innovative healthcare solutions to patients while achieving long-term growth objectives.
Vishal Arora - Chief Operating Officer
Vishal Arora, the Chief Operating Officer at Roche, directs internal scaling initiatives to optimize pharmaceutical manufacturing workflows. Overseeing global supply chain efficiency, the Chief Operating Officer ensures that production timelines align with international demand for oncology and immunology treatments. This leadership role involves streamlining cross-functional collaboration between research teams and commercial distribution networks to maintain high standards of quality control. By implementing advanced process automation, Vishal Arora directly impacts the operational agility of the organization. Ultimately, Arora secures the necessary infrastructure to support the rapid delivery of life-saving medicines to patients worldwide, reinforcing the company's position as a leader in the pharmaceutical sector.
Rupesh Chopra - Chief Operating Officer & Head of Cluster ( Cluster)
Rupesh Chopra, the Chief Operating Officer & Head of Cluster ( Cluster) at Roche, manages regional operational performance and market access strategies. Coordinating with local healthcare stakeholders, the Chief Operating Officer & Head of Cluster ( Cluster) ensures that the pharmaceutical and diagnostic divisions meet specific regional regulatory requirements. This leadership position involves overseeing the deployment of targeted therapies within the assigned cluster to maximize patient reach. By aligning local market activities with the broader corporate strategy, Rupesh Chopra drives sustainable growth and operational excellence. Ultimately, Chopra fosters strong partnerships with medical institutions, ensuring that the company's innovative healthcare solutions effectively address the unique needs of the patient populations within the designated geographic cluster.
Rajendra Dubey - Chief Operating Officer, MH and Punjab Cluster
Rajendra Dubey, the Chief Operating Officer, MH and Punjab Cluster at Roche, executes operational strategies tailored to the specific healthcare landscapes of the MH and Punjab regions. Directing the distribution of diagnostic products and pharmaceutical medicines, the Chief Operating Officer, MH and Punjab Cluster ensures consistent availability of critical treatments. This role involves managing local sales teams and navigating complex regional healthcare environments to expand the footprint of personalized medicine. By optimizing logistics and local engagement, Rajendra Dubey directly impacts the accessibility of advanced diagnostics for patients in these areas. Ultimately, Dubey strengthens the company's market presence by ensuring that operational activities remain responsive to the evolving demands of the regional healthcare sector.
Robert McRuer - Chief Technology Officer
Robert McRuer, the Chief Technology Officer at Roche, architects the digital infrastructure supporting diagnostic innovation and data-driven healthcare. Managing the integration of laboratory diagnostics with cloud-based analytics, the Chief Technology Officer drives the development of platforms that enable early disease detection. This role requires constant coordination with research scientists to ensure that technological tools facilitate personalized treatment decisions. By modernizing the digital ecosystem, Robert McRuer enhances the precision of diagnostic services across the global portfolio. Ultimately, McRuer maintains the technological edge necessary for the company to remain at the forefront of medical science, ensuring that data security and system reliability support the overarching mission of improving patient lives through advanced healthcare solutions.
Kristina Kallasmaa - Chief Marketing Officer & Site Manager
Kristina Kallasmaa, the Chief Marketing Officer & Site Manager at Roche, leads the commercial strategy and site-level operations to promote the company's innovative healthcare portfolio. Developing comprehensive marketing campaigns, the Chief Marketing Officer & Site Manager communicates the value of targeted therapies to healthcare providers and patients. This dual role involves overseeing facility management to ensure a productive environment for the local workforce. By aligning brand messaging with clinical evidence, Kristina Kallasmaa drives market adoption of new diagnostic and pharmaceutical solutions. Ultimately, Kallasmaa ensures that the site operates efficiently while simultaneously expanding the reach of the company's life-improving products, thereby supporting the broader organizational goal of transforming patient care through science-led marketing initiatives.
Rebecca Laurin - Governance & Strategic Alignment Leader & Chief of Staff
Rebecca Laurin, the Governance & Strategic Alignment Leader & Chief of Staff at Roche, coordinates executive decision-making processes to ensure alignment with the company's long-term strategic goals. Managing the flow of information between the C-suite and the Board, the Governance & Strategic Alignment Leader & Chief of Staff facilitates the execution of corporate initiatives across all divisions. This role involves overseeing governance frameworks to maintain compliance and operational integrity. By streamlining communication and project management, Rebecca Laurin enables the leadership team to focus on high-impact priorities. Ultimately, Laurin supports the organizational structure by ensuring that every strategic move remains consistent with the company's mission to pioneer innovative healthcare solutions and maintain global leadership in pharmaceuticals and diagnostics.
Alvin Raskina - Division For People & Culture Pharma Chief of Staff
Alvin Raskina, the Division For People & Culture Pharma Chief of Staff at Roche, directs human capital strategies to foster a high-performance culture within the pharmaceutical division. Overseeing talent development and organizational design, the Division For People & Culture Pharma Chief of Staff ensures that the workforce possesses the expertise required to advance scientific innovation. This role involves aligning internal culture with the company's commitment to personalized healthcare. By implementing initiatives that promote diversity and professional growth, Alvin Raskina strengthens the company's ability to attract and retain top-tier researchers and business experts. Ultimately, Raskina supports the organizational mission by cultivating an environment where employees feel empowered to contribute to the fight against serious diseases.
Explore Leadership Teams in Manufacturing
Sarepta Therapeutics, Inc. is a global commercial-stage biopharmaceutical company founded in 1980 and headquartered in Cambridge, Massachusetts. The company is focused on the discovery, development, and commercialization of precision genetic medicines for rare diseases, with particular leadership in Duchenne muscular dystrophy and limb-girdle muscular dystrophies. Sarepta's multi-platform Precision Genetic Medicine Engine spans gene therapy, RNA-targeted therapeutics, and gene editing modalities. The company holds multiple FDA-approved treatments and maintains a broad pipeline of programs across neuromuscular and central nervous system disorders. Sarepta operates globally with locations across North America, Europe, and Asia, and trades on the NASDAQ under the ticker symbol SRPT.
Company Leadership
ZG
BT
IE
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.
Company Leadership ES
NB
Eisai is a global pharmaceutical manufacturing company founded in 1941. The company develops and produces medicines while focusing on a human health care approach that extends beyond traditional pharmaceutical services. Eisai operates across multiple regions including North America, Europe, Asia Pacific, and the Middle East, with a strong presence in countries such as the United States, Japan, China, and the United Kingdom. The company maintains a significant focus on research and development in the pharmaceutical sector, with particular emphasis on patient-centered healthcare solutions. Eisai's business model encompasses both business-to-business and business-to-consumer operations, reflecting its comprehensive approach to healthcare delivery and pharmaceutical development.
Company Leadership
MM
Santen Pharmaceutical Co., Ltd., is a Japanese pharmaceutical company, specializing in ophthalmology. With its ophthalmic products Santen holds the top share within the Japanese market and is one of the leading ophthalmic companies worldwide, with its products being sold in over 50 countries. The company was founded in 1890 by Kenkichi Taguchi, as Taguchi Santendo, and in 1925, Santendo Co., Ltd. was established.
Company Leadership TI
RN
FA
Frequently Asked Questions Regarding Roche Top Executives and Leadership Team
